Clinical trial
Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy
NCT06222437 is registered in ClinicalTrials.gov with Methodist Health System as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy
- Lead sponsor
- Methodist Health System
- Phase
- Phase 1
- Overall status
- Withdrawn
- Start date
- February 28, 2026
- Completion date
- February 28, 2027
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.